Welcome to our dedicated page for TELESCOPE INNOVATIONS news (Ticker: TELIF), a resource for investors and traders seeking the latest updates and insights on TELESCOPE INNOVATIONS stock.
Telescope Innovations Corp. develops enabling technologies and services for pharmaceutical, high-value chemical, and related laboratory markets. Company news commonly covers Self-Driving Laboratories, the DirectInject-LC™ automated sampling and analysis product, contract research services, customer installations, technology collaborations, and technical outreach to scientific and investor audiences.
Updates also address financial results, product fulfillment, hiring and operating expenses tied to growth, and Telescope's lithium processing portfolio, including DualPure™ and ReCRFT™ technologies for battery-material applications. The company's announcements connect automation, chemical process development, and materials R&D with recurring disclosures on revenue drivers, partnerships, and commercialization activity.
Telescope Innovations (OTCQB: TELIF) will present at Planet MicroCap Las Vegas 2026 on June 17, 2026, at 4:30 pm PST. Dr. Jeffrey Sherman will discuss DirectInject-LC reaction sampling, the AGI SDA reactor collaboration, and recent Self-Driving Lab deployments in Korea, Europe, and at Pfizer.
Telescope Innovations (OTCQB: TELIF) announced that Founder and CTO Professor Jason Hein received the 2026 SCI Canada LeSueur Memorial Award. The honour recognizes his technical excellence and contributions to Canadian industry in chemical creativity and innovation.
The award highlights Hein’s work linking chemistry, automation, AI, and Self-Driving Lab technology.
Telescope Innovations (OTCQB: TELIF) signed an agreement to deploy a Self-Driving Lab (SDL) platform for a major global pharmaceutical company at its European operations. This will be Telescope's third SDL deployment in its 2026 fiscal year.
Earlier in the fiscal year, SDL platforms were installed at the Korean Pharmaceutical and Biopharma Manufacturers Association and at Pfizer. According to Telescope, adding a third top-tier pharma partner highlights growing international demand for its autonomous lab technology.
Telescope Innovations (OTCQB: TELIF) outlined its spring 2026 conference and events lineup, targeting pharmaceutical, academic, and investor audiences.
The company is presenting and exhibiting its Self-Driving Labs and DirectInject-LC technologies, while CTO Dr. Jason Hein delivers multiple keynotes and accepts the LaSueur Memorial Award, alongside dedicated investor engagement events.
Telescope Innovations (OTCQB: TELIF) reported Q2 FY2026 results for the quarter ended February 28, 2026, with revenues of $1.64M (up from $1.00M in Q2 FY2025) and a year-to-date gross revenue of $4.3M versus $2.2M a year earlier. Adjusted EBITA loss was $0.71M, in line with management expectations.
Revenue growth was driven by delivery of Self-Driving Laboratories, including a second SDL delivered to Pfizer. Expenses rose to $3.11M to support hiring, product fulfillment and sales activity. Telescope also expanded lab space for lithium processing and reported battery-grade lithium from its ReCRFT process.
Telescope Innovations (OTCQB: TELIF) announced that Dr. Joel M. Hawkins has expanded his consulting role to support the company’s work in automated chemistry sampling and Self-Driving Laboratories (SDLs). Dr. Hawkins brings experience automating complex chemistry workflows and prior collaborations with Pfizer and Technobis.
He will support development of the DirectInject-LC platform, contribute to a Telescope–AGI reactor collaboration, and help scale SDL deployments integrating robotics, inline analytics, and AI.
Telescope Innovations (OTCQB: TELIF) signed a Development and Collaboration Agreement with AGI Group's Synthesis, Digitization, and Automation program (AGI SDA) on March 16, 2026 to co-develop an AI-ready chemical reactor and sampling platform.
The partners aim to integrate Telescope's DirectInject-LC sampling technology with AGI's reactor and SYNTO platform, with a broader effort involving six major biopharma companies and a planned SYNTO release mid 2027.
Telescope Innovations (OTCQB: TELIF) has rescoped its prior digital marketing agreement with Gold Standard Media, which refunded $300,000 in previously paid fees to the company. Telescope engaged Curzio Research Holdings for digital marketing and investor awareness services under a three-month agreement starting March 1, 2026, with an upfront payment of USD $300,000. Curzio and its CEO Frank Curzio are at arm's length and report no ownership in Telescope. Curzio is US-based and provided contact details for investor inquiries.
Telescope Innovations (OTCQB: TELIF) installed a second Self-Driving Laboratory (SDL) at Pfizer under a multi-year agreement; installation completed in January 2026.
The second Physical AI platform advances a move from collaborative R&D toward potential full-scale deployment, aiming to shorten development timelines and reduce chemistry research costs via AI-guided experimentation and robotic automation.
Telescope Innovations (OTCQB: TELIF) reported Q1 fiscal 2026 results for the quarter ended Nov 30, 2025: revenues CAD $2.70M (Q1 FY2025: $1.20M) and an adjusted EBITA loss CAD $0.83M (Q1 FY2025: loss $0.10M). Revenue growth was driven by DirectInject-LC product sales, Contract Research Services and delivery of the first Self Driving Laboratory to KPBMA.
Expenses rose as the company invested in hiring, parts, travel and professional services. Telescope closed a $6.50M capital raise and received conditional government funding of $3.60M for lithium recycling and solid-state battery work.